Copyright Reports & Markets. All rights reserved.

Global and United States Cellular Human Tissue-engineered Skin Substitute Market Report & Forecast 2022-2028

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Cellular Human Tissue-engineered Skin Substitute Product Introduction
    • 1.2 Global Cellular Human Tissue-engineered Skin Substitute Outlook 2017 VS 2022 VS 2028
      • 1.2.1 Global Cellular Human Tissue-engineered Skin Substitute Sales in US$ Million for the Year 2017-2028
      • 1.2.2 Global Cellular Human Tissue-engineered Skin Substitute Sales in Volume for the Year 2017-2028
    • 1.3 United States Cellular Human Tissue-engineered Skin Substitute Outlook 2017 VS 2022 VS 2028
      • 1.3.1 United States Cellular Human Tissue-engineered Skin Substitute Sales in US$ Million for the Year 2017-2028
      • 1.3.2 United States Cellular Human Tissue-engineered Skin Substitute Sales in Volume for the Year 2017-2028
    • 1.4 Cellular Human Tissue-engineered Skin Substitute Market Size, United States VS Global, 2017 VS 2022 VS 2028
      • 1.4.1 The Market Share of United States Cellular Human Tissue-engineered Skin Substitute in Global, 2017 VS 2022 VS 2028
      • 1.4.2 The Growth Rate of Cellular Human Tissue-engineered Skin Substitute Market Size, United States VS Global, 2017 VS 2022 VS 2028
    • 1.5 Cellular Human Tissue-engineered Skin Substitute Market Dynamics
      • 1.5.1 Cellular Human Tissue-engineered Skin Substitute Industry Trends
      • 1.5.2 Cellular Human Tissue-engineered Skin Substitute Market Drivers
      • 1.5.3 Cellular Human Tissue-engineered Skin Substitute Market Challenges
      • 1.5.4 Cellular Human Tissue-engineered Skin Substitute Market Restraints
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Market by Type

    • 2.1 Cellular Human Tissue-engineered Skin Substitute Market Segment by Type
      • 2.1.1 Cellular Allogeneic
      • 2.1.2 Cellular Autologous
      • 2.1.3 Others
    • 2.2 Global Cellular Human Tissue-engineered Skin Substitute Market Size by Type
      • 2.2.1 Global Cellular Human Tissue-engineered Skin Substitute Sales in Value, by Type (2017, 2022 & 2028)
      • 2.2.2 Global Cellular Human Tissue-engineered Skin Substitute Sales in Volume, by Type (2017, 2022 & 2028)
      • 2.2.3 Global Cellular Human Tissue-engineered Skin Substitute Average Selling Price (ASP) by Type (2017, 2022 & 2028)
    • 2.3 United States Cellular Human Tissue-engineered Skin Substitute Market Size by Type
      • 2.3.1 United States Cellular Human Tissue-engineered Skin Substitute Sales in Value, by Type (2017, 2022 & 2028)
      • 2.3.2 United States Cellular Human Tissue-engineered Skin Substitute Sales in Volume, by Type (2017, 2022 & 2028)
      • 2.3.3 United States Cellular Human Tissue-engineered Skin Substitute Average Selling Price (ASP) by Type (2017, 2022 & 2028)

    3 Market by Application

    • 3.1 Cellular Human Tissue-engineered Skin Substitute Market Segment by Application
      • 3.1.1 Hospitals
      • 3.1.2 Specialty Clinics
      • 3.1.3 Wound Care Centers
    • 3.2 Global Cellular Human Tissue-engineered Skin Substitute Market Size by Application
      • 3.2.1 Global Cellular Human Tissue-engineered Skin Substitute Sales in Value, by Application (2017, 2022 & 2028)
      • 3.2.2 Global Cellular Human Tissue-engineered Skin Substitute Sales in Volume, by Application (2017, 2022 & 2028)
      • 3.3.3 Global Cellular Human Tissue-engineered Skin Substitute Average Selling Price (ASP) by Application (2017, 2022 & 2028)
    • 3.3 United States Cellular Human Tissue-engineered Skin Substitute Market Size by Application
      • 3.3.1 United States Cellular Human Tissue-engineered Skin Substitute Sales in Value, by Application (2017, 2022 & 2028)
      • 3.3.2 United States Cellular Human Tissue-engineered Skin Substitute Sales in Volume, by Application (2017, 2022 & 2028)
      • 3.3.3 United States Cellular Human Tissue-engineered Skin Substitute Average Selling Price (ASP) by Application (2017, 2022 & 2028)

    4 Global Cellular Human Tissue-engineered Skin Substitute Competitor Landscape by Company

    • 4.1 Global Cellular Human Tissue-engineered Skin Substitute Market Size by Company
      • 4.1.1 Top Global Cellular Human Tissue-engineered Skin Substitute Manufacturers Ranked by Revenue (2021)
      • 4.1.2 Global Cellular Human Tissue-engineered Skin Substitute Revenue by Manufacturer (2017-2022)
      • 4.1.3 Global Cellular Human Tissue-engineered Skin Substitute Sales by Manufacturer (2017-2022)
      • 4.1.4 Global Cellular Human Tissue-engineered Skin Substitute Price by Manufacturer (2017-2022)
    • 4.2 Global Cellular Human Tissue-engineered Skin Substitute Concentration Ratio (CR)
      • 4.2.1 Cellular Human Tissue-engineered Skin Substitute Market Concentration Ratio (CR) (2017-2022)
      • 4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Cellular Human Tissue-engineered Skin Substitute in 2021
      • 4.2.3 Global Cellular Human Tissue-engineered Skin Substitute Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    • 4.3 Global Cellular Human Tissue-engineered Skin Substitute Manufacturing Base Distribution, Product Type
      • 4.3.1 Global Cellular Human Tissue-engineered Skin Substitute Manufacturers, Headquarters and Distribution of Producing Region
      • 4.3.2 Manufacturers Cellular Human Tissue-engineered Skin Substitute Product Type
      • 4.3.3 Date of International Manufacturers Enter into Cellular Human Tissue-engineered Skin Substitute Market
    • 4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
    • 4.5 United States Cellular Human Tissue-engineered Skin Substitute Market Size by Company
      • 4.5.1 Top Cellular Human Tissue-engineered Skin Substitute Players in United States, Ranked by Revenue (2021)
      • 4.5.2 United States Cellular Human Tissue-engineered Skin Substitute Revenue by Players (2020, 2021 & 2022)
      • 4.5.3 United States Cellular Human Tissue-engineered Skin Substitute Sales by Players (2020, 2021 & 2022)

    5 Global Cellular Human Tissue-engineered Skin Substitute Market Size by Region

    • 5.1 Global Cellular Human Tissue-engineered Skin Substitute Market Size by Region: 2017 VS 2022 VS 2028
    • 5.2 Global Cellular Human Tissue-engineered Skin Substitute Market Size in Volume by Region (2017-2028)
      • 5.2.1 Global Cellular Human Tissue-engineered Skin Substitute Sales in Volume by Region: 2017-2022
      • 5.2.2 Global Cellular Human Tissue-engineered Skin Substitute Sales in Volume Forecast by Region (2023-2028)
    • 5.3 Global Cellular Human Tissue-engineered Skin Substitute Market Size in Value by Region (2017-2028)
      • 5.3.1 Global Cellular Human Tissue-engineered Skin Substitute Sales in Value by Region: 2017-2022
      • 5.3.2 Global Cellular Human Tissue-engineered Skin Substitute Sales in Value by Region: 2023-2028

    6 Segment in Region Level & Country Level

    • 6.1 North America
      • 6.1.1 North America Cellular Human Tissue-engineered Skin Substitute Market Size YoY Growth 2017-2028
      • 6.1.2 North America Cellular Human Tissue-engineered Skin Substitute Market Facts & Figures by Country (2017, 2022 & 2028)
      • 6.1.3 United States
      • 6.1.4 Canada
    • 6.2 Asia-Pacific
      • 6.2.1 Asia-Pacific Cellular Human Tissue-engineered Skin Substitute Market Size YoY Growth 2017-2028
      • 6.2.2 Asia-Pacific Cellular Human Tissue-engineered Skin Substitute Market Facts & Figures by Region (2017, 2022 & 2028)
      • 6.2.3 China
      • 6.2.4 Japan
      • 6.2.5 South Korea
      • 6.2.6 India
      • 6.2.7 Australia
      • 6.2.8 China Taiwan
      • 6.2.9 Indonesia
      • 6.2.10 Thailand
      • 6.2.11 Malaysia
    • 6.3 Europe
      • 6.3.1 Europe Cellular Human Tissue-engineered Skin Substitute Market Size YoY Growth 2017-2028
      • 6.3.2 Europe Cellular Human Tissue-engineered Skin Substitute Market Facts & Figures by Country (2017, 2022 & 2028)
      • 6.3.3 Germany
      • 6.3.4 France
      • 6.3.5 U.K.
      • 6.3.6 Italy
      • 6.3.7 Russia
    • 6.4 Latin America
      • 6.4.1 Latin America Cellular Human Tissue-engineered Skin Substitute Market Size YoY Growth 2017-2028
      • 6.4.2 Latin America Cellular Human Tissue-engineered Skin Substitute Market Facts & Figures by Country (2017, 2022 & 2028)
      • 6.4.3 Mexico
      • 6.4.4 Brazil
      • 6.4.5 Argentina
    • 6.5 Middle East and Africa
      • 6.5.1 Middle East and Africa Cellular Human Tissue-engineered Skin Substitute Market Size YoY Growth 2017-2028
      • 6.5.2 Middle East and Africa Cellular Human Tissue-engineered Skin Substitute Market Facts & Figures by Country (2017, 2022 & 2028)
      • 6.5.3 Turkey
      • 6.5.4 Saudi Arabia
      • 6.5.5 UAE

    7 Company Profiles

    • 7.1 Allergan (AbbVie)
      • 7.1.1 Allergan (AbbVie) Corporation Information
      • 7.1.2 Allergan (AbbVie) Description and Business Overview
      • 7.1.3 Allergan (AbbVie) Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2017-2022)
      • 7.1.4 Allergan (AbbVie) Cellular Human Tissue-engineered Skin Substitute Products Offered
      • 7.1.5 Allergan (AbbVie) Recent Development
    • 7.2 AlloSource
      • 7.2.1 AlloSource Corporation Information
      • 7.2.2 AlloSource Description and Business Overview
      • 7.2.3 AlloSource Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2017-2022)
      • 7.2.4 AlloSource Cellular Human Tissue-engineered Skin Substitute Products Offered
      • 7.2.5 AlloSource Recent Development
    • 7.3 Organogenesis
      • 7.3.1 Organogenesis Corporation Information
      • 7.3.2 Organogenesis Description and Business Overview
      • 7.3.3 Organogenesis Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2017-2022)
      • 7.3.4 Organogenesis Cellular Human Tissue-engineered Skin Substitute Products Offered
      • 7.3.5 Organogenesis Recent Development
    • 7.4 BD
      • 7.4.1 BD Corporation Information
      • 7.4.2 BD Description and Business Overview
      • 7.4.3 BD Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2017-2022)
      • 7.4.4 BD Cellular Human Tissue-engineered Skin Substitute Products Offered
      • 7.4.5 BD Recent Development
    • 7.5 Smith & Nephew
      • 7.5.1 Smith & Nephew Corporation Information
      • 7.5.2 Smith & Nephew Description and Business Overview
      • 7.5.3 Smith & Nephew Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2017-2022)
      • 7.5.4 Smith & Nephew Cellular Human Tissue-engineered Skin Substitute Products Offered
      • 7.5.5 Smith & Nephew Recent Development
    • 7.6 Integra LifeSciences
      • 7.6.1 Integra LifeSciences Corporation Information
      • 7.6.2 Integra LifeSciences Description and Business Overview
      • 7.6.3 Integra LifeSciences Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2017-2022)
      • 7.6.4 Integra LifeSciences Cellular Human Tissue-engineered Skin Substitute Products Offered
      • 7.6.5 Integra LifeSciences Recent Development
    • 7.7 Synthes (Johnson & Johnson)
      • 7.7.1 Synthes (Johnson & Johnson) Corporation Information
      • 7.7.2 Synthes (Johnson & Johnson) Description and Business Overview
      • 7.7.3 Synthes (Johnson & Johnson) Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2017-2022)
      • 7.7.4 Synthes (Johnson & Johnson) Cellular Human Tissue-engineered Skin Substitute Products Offered
      • 7.7.5 Synthes (Johnson & Johnson) Recent Development
    • 7.8 Axogen
      • 7.8.1 Axogen Corporation Information
      • 7.8.2 Axogen Description and Business Overview
      • 7.8.3 Axogen Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2017-2022)
      • 7.8.4 Axogen Cellular Human Tissue-engineered Skin Substitute Products Offered
      • 7.8.5 Axogen Recent Development
    • 7.9 Vericel Corporation
      • 7.9.1 Vericel Corporation Corporation Information
      • 7.9.2 Vericel Corporation Description and Business Overview
      • 7.9.3 Vericel Corporation Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2017-2022)
      • 7.9.4 Vericel Corporation Cellular Human Tissue-engineered Skin Substitute Products Offered
      • 7.9.5 Vericel Corporation Recent Development
    • 7.10 LifeNet Health
      • 7.10.1 LifeNet Health Corporation Information
      • 7.10.2 LifeNet Health Description and Business Overview
      • 7.10.3 LifeNet Health Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2017-2022)
      • 7.10.4 LifeNet Health Cellular Human Tissue-engineered Skin Substitute Products Offered
      • 7.10.5 LifeNet Health Recent Development
    • 7.11 MTF Biologics
      • 7.11.1 MTF Biologics Corporation Information
      • 7.11.2 MTF Biologics Description and Business Overview
      • 7.11.3 MTF Biologics Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2017-2022)
      • 7.11.4 MTF Biologics Cellular Human Tissue-engineered Skin Substitute Products Offered
      • 7.11.5 MTF Biologics Recent Development
    • 7.12 Arthrex
      • 7.12.1 Arthrex Corporation Information
      • 7.12.2 Arthrex Description and Business Overview
      • 7.12.3 Arthrex Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2017-2022)
      • 7.12.4 Arthrex Products Offered
      • 7.12.5 Arthrex Recent Development
    • 7.13 Wright Medical Group NV (Stryker)
      • 7.13.1 Wright Medical Group NV (Stryker) Corporation Information
      • 7.13.2 Wright Medical Group NV (Stryker) Description and Business Overview
      • 7.13.3 Wright Medical Group NV (Stryker) Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2017-2022)
      • 7.13.4 Wright Medical Group NV (Stryker) Products Offered
      • 7.13.5 Wright Medical Group NV (Stryker) Recent Development
    • 7.14 Cook Biotech Incorporated
      • 7.14.1 Cook Biotech Incorporated Corporation Information
      • 7.14.2 Cook Biotech Incorporated Description and Business Overview
      • 7.14.3 Cook Biotech Incorporated Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2017-2022)
      • 7.14.4 Cook Biotech Incorporated Products Offered
      • 7.14.5 Cook Biotech Incorporated Recent Development
    • 7.15 Aroa Biosurgery
      • 7.15.1 Aroa Biosurgery Corporation Information
      • 7.15.2 Aroa Biosurgery Description and Business Overview
      • 7.15.3 Aroa Biosurgery Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2017-2022)
      • 7.15.4 Aroa Biosurgery Products Offered
      • 7.15.5 Aroa Biosurgery Recent Development
    • 7.16 Surgalign Holdings
      • 7.16.1 Surgalign Holdings Corporation Information
      • 7.16.2 Surgalign Holdings Description and Business Overview
      • 7.16.3 Surgalign Holdings Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2017-2022)
      • 7.16.4 Surgalign Holdings Products Offered
      • 7.16.5 Surgalign Holdings Recent Development

    8 Industry Chain and Sales Channels Analysis

    • 8.1 Cellular Human Tissue-engineered Skin Substitute Industry Chain Analysis
    • 8.2 Cellular Human Tissue-engineered Skin Substitute Key Raw Materials
      • 8.2.1 Key Raw Materials
      • 8.2.2 Cellular Human Tissue-engineered Skin Substitute Distributors
    • 8.3 Cellular Human Tissue-engineered Skin Substitute Production Mode & Process
    • 8.4 Cellular Human Tissue-engineered Skin Substitute Sales and Marketing
      • 8.4.1 Cellular Human Tissue-engineered Skin Substitute Sales Channels
      • 8.4.2 Cellular Human Tissue-engineered Skin Substitute Distributors
    • 8.5 Cellular Human Tissue-engineered Skin Substitute Customers

    9 Research Findings and Conclusion

      10 Appendix

      • 10.1 Research Methodology
        • 10.1.1 Methodology/Research Approach
        • 10.1.2 Data Source
      • 10.2 Author Details

      Summary:

      Market Analysis and Insights: Global and United States Cellular Human Tissue-engineered Skin Substitute Market
      This report focuses on global and United States Cellular Human Tissue-engineered Skin Substitute market, also covers the segmentation data of other regions in regional level and county level.
      Due to the COVID-19 pandemic, the global Cellular Human Tissue-engineered Skin Substitute market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, Cellular Allogeneic accounting for % of the Cellular Human Tissue-engineered Skin Substitute global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Hospitals was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
      In United States the Cellular Human Tissue-engineered Skin Substitute market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
      Global Cellular Human Tissue-engineered Skin Substitute Scope and Market Size
      Cellular Human Tissue-engineered Skin Substitute market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Cellular Human Tissue-engineered Skin Substitute market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
      For United States market, this report focuses on the Cellular Human Tissue-engineered Skin Substitute market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
      Segment by Type, the Cellular Human Tissue-engineered Skin Substitute market is segmented into
      Cellular Allogeneic
      Cellular Autologous
      Others
      Segment by Application, the Cellular Human Tissue-engineered Skin Substitute market is segmented into
      Hospitals
      Specialty Clinics
      Wound Care Centers
      Regional and Country-level Analysis
      By Region
      North America
      United States
      Canada
      Europe
      Germany
      France
      U.K.
      Italy
      Russia
      Asia-Pacific
      China
      Japan
      South Korea
      India
      Australia
      China Taiwan
      Indonesia
      Thailand
      Malaysia
      Latin America
      Mexico
      Brazil
      Argentina
      Middle East & Africa
      Turkey
      Saudi Arabia
      UAE
      Competitive Landscape and Cellular Human Tissue-engineered Skin Substitute Market Share Analysis
      Cellular Human Tissue-engineered Skin Substitute market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2017-2022. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2017-2022. Details included are company description, major business, company total revenue and the sales, revenue generated in Cellular Human Tissue-engineered Skin Substitute business, the date to enter into the Cellular Human Tissue-engineered Skin Substitute market, Cellular Human Tissue-engineered Skin Substitute product introduction, recent developments, etc.
      The major vendors covered:
      Allergan (AbbVie)
      AlloSource
      Organogenesis
      BD
      Smith & Nephew
      Integra LifeSciences
      Synthes (Johnson & Johnson)
      Axogen
      Vericel Corporation
      LifeNet Health
      MTF Biologics
      Arthrex
      Wright Medical Group NV (Stryker)
      Cook Biotech Incorporated
      Aroa Biosurgery
      Surgalign Holdings
      Buy now